Physician
Pulmonology
Dr. Paul M. Dorinsky, MD
Dr. Paul M. Dorinsky is an expert in the field of Pulmonology. He researched medicine at The Ohio State University College of Medicine. Paul Dorinsky is also a published doctor. He has 68 paper published. The most recent paper is: Ischemia/reperfusion injury to the ileum does not account for the ileal VO2-DO2 alterations induced by endotoxin. He accepts Medicare.
Publications
- Impact of exhaled nitric oxide measurements on treatment decisions in an Asthma specialty clinic.
- Tolerability of a salmeterol xinafoate/fluticasone propionate hydrofluoroalkane metered-dose inhaler in adolescent and adult patients with persistent Asthma: a 52-week...
- Safety of long-acting beta-agonists.
- Salmeterol response is not affected by beta2-adrenergic receptor genotype in subjects with persistent Asthma.
- Control of airway inflammation maintained at a lower steroid dose with 100/50 microg of fluticasone propionate/salmeterol.
- Variability in Asthma severity in pediatric subjects with Asthma previously receiving short-acting beta2-agonists.
- Fluticasone propionate nasal spray is superior to montelukast for allergic rhinitis while neither affects overall Asthma control.
- Effect of fluticasone/salmeterol administered via a single device on exercise-induced bronchospasm in patients with persistent Asthma.
- Asthma variability in patients previously treated with beta2-agonists alone.
- Patient perceptions of an inhaled Asthma medication administered as an inhalation powder via the Diskus or as an inhalation aerosol via a metered-dose inhaler.
- Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled wi...
- Combination therapy with inhaled long-acting beta2-agonists and inhaled corticosteroids: a paradigm shift in Asthma management.
- Dual components of optimal Asthma therapy: scientific and clinical rationale for the use of long-acting beta-agonists with inhaled corticosteroids.
- Comparison of fluticasone propionate-salmeterol combination therapy and montelukast in patients who are symptomatic on short-acting beta(2)-agonists alone.
- Use of changes in symptoms to predict changes in lung function in assessing the response to Asthma therapy.
- Ileal VO(2)-O(2) alterations induced by endotoxin correlate with severity of mitochondrial injury.
- The combination of ipratropium and albuterol optimizes Pulmonary function reversibility testing in patients with COPD.
- Ischemia/reperfusion injury to the ileum does not account for the ileal VO2-DO2 alterations induced by endotoxin.
- Endotoxin-induced ileal Vo2-Do2 alterations do not correlate with the severity of ileal injury.
- Treating respiratory Infections in the elderly: current strategies and considerations.
- Diagnosis and therapy of acute Respiratory distress syndrome in adults: an international survey.
- Metabolic consequences of sepsis. Correlation with altered intracellular calcium homeostasis.
- Acid aspiration results in ileal injury without altering ileal V(O2)-D(O2) relationships.
- Acid aspiration-induced acute Lung injury causes leukocyte-dependent systemic organ injury.
- Immunologic therapy for ARDS, septic shock, and multiple-organ Failure.
- Oxygen uptake-oxygen delivery alterations in the isolated liver after hydrogen peroxide challenge.
- Cryptogenic bronchiolitis.
- Paraaminosalicylate blocks that ileal injury induced by phorbol myristate acetate.
- Regional blood flow distribution in endotoxin-treated dogs: modification by ibuprofen.
- An overview of multiple organ dysfunction syndrome.
- Gastrointestinal tract dysfunction in critical illness: pathophysiology and interaction with acute Lung injury in adult respiratory distress syndrome/multiple organ dy...
- Anti-CD18 antibody does not block ileal injury induced by phorbol myristate acetate.
- The effect of PEEP on cardiac output.
- Hypoxia results in an increase in total systemic shunt flow in dogs.
- Adult bronchiolitis. Evaluation by bronchoalveolar lavage and response to prednisone therapy.
- Chronic bronchitis. Oxidant damage by leukocytes.
- Alterations in regional blood flow during positive end-expiratory pressure ventilation.
- Relationships of oxygen uptake and oxygen delivery in Respiratory failure not due to the adult Respiratory distress syndrome.
- Oxygen distribution and utilization after phorbol myristate acetate-induced Lung injury.
- Lung neutrophils in the adult respiratory distress syndrome. Clinical and pathophysiologic significance.
- Neutrophil accumulation and structural changes in nonPulmonary organs after acute lung injury induced by phorbol myristate acetate.
- Validity of bronchoalveolar lavage in acute Lung injury: recovered cells accurately reflect changes in the Lung parenchyma.
- Mechanisms of multiple nonPulmonary organ failure in ARDS.
- Bronchiolitis in adults. A reversible cause of airway obstruction associated with airway neutrophils and neutrophil products.
- Analysis of airflow obstruction by bronchoalveolar lavage following bone marrow transplantation. Implications for pathogenesis and treatment.
- Multiple organ Failure.
- Increased intestinal protein permeability in a model of Lung injury induced by phorbol myristate acetate.
- Cost-effectiveness comparison of salmeterol/fluticasone propionate versus montelukast in the treatment of adults with persistent Asthma.
- Loss of response to treatment with leukotriene receptor antagonists but not inhaled corticosteroids in patients over 50 years of age.
- Fluticasone propionate/salmeterol combination compared with montelukast for the treatment of persistent Asthma.
- Improved ability to perform strenuous activities after treatment with fluticasone propionate/salmeterol combination in patients with persistent Asthma.
- Efficacy and safety of fluticasone propionate 44 microg/salmeterol 21 microg administered in a hydrofluoroalkane metered-dose inhaler as an initial Asthma maintenance ...
- Efficacy and safety of fluticasone propionate/salmeterol HFA 134A MDI in patients with mild-to-moderate persistent Asthma.
- Effect of fluticasone propionate and salmeterol in a single device, fluticasone propionate, and montelukast on overall Asthma control, exacerbations, and costs.
- The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent Asthma.
- Fluticasone propionate and salmeterol administered via Diskus compared with salmeterol or fluticasone propionate alone in patients suboptimally controlled with short-a...
- Cost effectiveness of fluticasone propionate plus salmeterol versus fluticasone propionate plus montelukast in the treatment of persistent Asthma.
- Determining economic feasibility of fluticasone propionate-salmeterol vs montelukast in the treatment of persistent Asthma using a net benefit approach and cost-effect...
- The safety of twice-daily treatment with fluticasone propionate and salmeterol in pediatric patients with persistent Asthma.
- Efficacy and tolerability of fluticasone propionate/salmeterol administered twice daily via hydrofluoroalkane 134a metered-dose inhaler in adolescent and adult patient...
- The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for Asthma or usual pharmacotherapy plus salmeterol.
- Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs. large-particle chlorofluorocarbon-beclometasone: a real-world observational study.
- Montelukast added to fluticasone propionate does not alter inflammation or outcomes.
- Prescribing practices and Asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study.
- Deterioration in Asthma control when subjects receiving fluticasone propionate/salmeterol 100/50 mcg Diskus are "stepped-down".
- Does measuring BHR add to guideline derived clinical measures in determining treatment for patients with persistent Asthma?
- Efficacy and safety of fluticasone propionate/salmeterol 250/50 mcg Diskus administered once daily.
Schools
Ohio State University College of Medicine
Ohio State University Hospital
Conditions Treated
- Asthma
- Bronchiectasis
- Chronic Pulmonary Heart Diseases (incl. Pulmonary Hypertension)
- COPD (Chronic Obstructive Pulmonary Disease)
- View All
Doctors Specialties
- Critical Care Medicine
- Pulmonology
Accepted Insurances
- Aetna HMO
- Choice Plus POS II
- Cigna PPO
- Great West Healthcare-Cigna PPO
- Wellpath Preferred PPO
- First Health (Coventry Health Care) PPO
- Choice Care PPO
Education
-
Ohio State University Hospital -
The Ohio State University College of Medicine
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1710050539 |
| Last Name Of The Provider | DORINSKY |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
Rakeshkumar P. Patel, PT
 This Doctor is OpenDoctor Recommended.
|
|
|
Conrad C. Reed, MB
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert B. Weinberg, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Riva Das, MD |
|
|
Dr. Christopher G. Bosse, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rajkumar R. Dasgupta, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stanley P. Silverman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joseph G. Crocetti Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard E. Friedenheim, MD
This Doctor is OpenDoctor Recommended.
|